About: Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development
Creator	Li, Zhong Li, Hongmin Samrat, Subodh Tharappel, Anil
Source	Elsevier; Medline; PMC
abstract	The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more strongly than SARS-CoV to the same host receptor, angiotensin-converting enzyme 2 (ACE2). Previously, several methods to develop a vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since SARS-CoV-2 uses the spike (S) protein for entry to the host cell, it is one of the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In this review, we have summarised the characteristics of the S protein, as well as the different approaches being used for the development of vaccines and/or therapeutics based on the S protein.
has issue date	2020-08-23(xsd:dateTime)
bibo:doi	10.1016/j.virusres.2020.198141
bibo:pmid	32846196
has license	no-cc
sha1sum (hex)	79cdafe81622d86941277bdf6af4fc7b8f72f3c5
schema:url	https://doi.org/10.1016/j.virusres.2020.198141
resource representing a document's title	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development
has PubMed Central identifier	PMC7443330
has PubMed identifier	32846196
schema:publication	Virus Res
resource representing a document's body	covid:79cdafe81622d86941277bdf6af4fc7b8f72f3c5#body_text
is schema:about of	named entity 'vaccine' named entity 'protein' named entity 'ACE2' named entity 'binds' named entity 'Journal' named entity 'vaccine' named entity 'therapeutic development' named entity 'therapeutic development' named entity 'EMA' named entity 'nCoV' named entity 'COVID-19' named entity 'viruses' named entity 'let-7' named entity 'SARS' named entity 'ADE' named entity 'MERS-CoV' named entity 'rhesus macaques' named entity 'protein' named entity 'monoclonal antibodies' named entity 'RBD' named entity 'RBD' named entity 'ADE' named entity 'RBD' named entity 'nanobody' named entity 'case fatality rate' named entity 'COVID' named entity 'Coronaviridae' named entity 'Imperial College London' named entity 'SARS-CoV' named entity '2019-nCoV' named entity 'vaccine' named entity 'viral entry' named entity 'protein' named entity 'antibodies' named entity 'SARS' named entity 'CD8+ T-cell' named entity 'highly contagious' named entity 'caplacizumab' named entity 'SARS-CoV-2' named entity 'nanobodies' named entity 'North America' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'CD38' named entity 'ACE2' named entity 'protein' named entity 'SARS-CoV2' named entity 'N-terminal' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'immunization' named entity 'protein' named entity 'neutralizing antibodies' named entity 'RBD' named entity 'vaccine' named entity 'SARS-CoV' named entity 'vaccine' named entity 'protein' named entity '2019-nCoV' named entity 'protein' named entity 'CoV' named entity 'COVID' named entity 'virus replication' named entity 'MERS-CoV' named entity 'vaccine' named entity 'IC50' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'animal models' named entity 'RBD' named entity 'HIV' named entity 'ADE' named entity 'SARS' named entity 'HCV' named entity 'endothelin receptor type B' named entity 'ADE' named entity 'pathogenesis' named entity 'ACE2 receptor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software